Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies


Itepekimab met the primary endpoint in one of two COPD phase 3 studies

More:
Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies

Related Posts